Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination refers to the co-administration of the Bacillus Calmette-Guérin (BCG) vaccine and the Yellow Fever vaccine, specifically within the context of clinical research conducted by the South Australian Health and Medical Research Institute (SAHMRI). The BCG vaccine is a live-attenuated strain of *Mycobacterium bovis* used primarily for the prevention of tuberculosis, while the Yellow Fever vaccine is a live-attenuated viral vaccine (typically the 17D strain). The study investigates how the gut microbiota influences the immune response to these vaccines, focusing on both the specific protection against tuberculosis and the non-specific 'trained immunity' effects that BCG may provide against heterologous challenges like the Yellow Fever virus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BCG vaccine + Yellow Fever vaccine.